BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $21
Zevra’s Lead Drug Faces Potential European Setback – ZVRA Stock Heads For Worst Day In A Month
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Zevra Therapeutics Says CHMP Adopts Negative Opinion On MAA For Arimoclomol For Treatment Of Niemann-Pick Disease Type C; European Commission Expected To Issue Final Decision On MAA Within 67 Days
Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade
Zevra (ZVRA) Q3 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. Q3 2026 Earnings Call Summary
Zevra Therapeutics (NASDAQ:ZVRA) Clears All Eight Growth Rules
Zevra Therapeutics Inc (ZVRA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 45% as MIPLYFFA ...
Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript
Zevra Therapeutics Q3 Earnings Call Highlights
Zevra Therapeutics: Q3 Earnings Snapshot
Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics Q3 2026 Earnings Call Transcript
Zevra Therapeutics Q3 EPS $0.26 Beats $0.16 Estimate, Sales $37.756M Beat $37.079M Estimate
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zevra Therapeutics to Present at Upcoming Investor Conferences
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.